Who are Romosozumab Prefilled Syringe's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Romosozumab and Denosumab Cycle Therapy, EVENITY, Romosozumab followed by Denosumab, Evenity, Placebo to Romosozumab, romosozumab HCP administration with PFS.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/romosozumab-prefilled-syringe.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Romosozumab Prefilled Syringe — Competitive Intelligence Brief

Romosozumab Prefilled Syringe (Romosozumab Prefilled Syringe) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Bone disorders.

phase 3 Monoclonal antibody Sclerostin Bone disorders Small molecule Live · refreshed every 30 min

Target snapshot

Romosozumab Prefilled Syringe (Romosozumab Prefilled Syringe) — Karen Klahr Miller, MD. Romosozumab Prefilled Syringe is a monoclonal antibody that targets sclerostin to increase bone formation and decrease bone resorption.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Romosozumab Prefilled Syringe TARGET	Romosozumab Prefilled Syringe	Karen Klahr Miller, MD	phase 3	Monoclonal antibody	Sclerostin
Romosozumab and Denosumab Cycle Therapy	Romosozumab and Denosumab Cycle Therapy	National Taiwan University Hospital	marketed	Bone-forming agent and antiresorptive agent combination therapy	Sclerostin (romosozumab); RANKL (denosumab)
EVENITY	ROMOSOZUMAB-AQQG	AMGEN INC	marketed		Sclerostin
Romosozumab followed by Denosumab	Romosozumab followed by Denosumab	National Taiwan University Hospital	marketed	Sclerostin inhibitor followed by RANKL inhibitor	Sclerostin (romosozumab); RANKL (Denosumab)
Evenity	romosozumab	Amgen	marketed		Sclerostin
Placebo to Romosozumab	Placebo to Romosozumab	Amgen	phase 3	Sclerostin inhibitor monoclonal antibody	Sclerostin (SOST protein)
romosozumab HCP administration with PFS	romosozumab HCP administration with PFS	Amgen	phase 3	Sclerostin inhibitor	Sclerostin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

Pfizer · 7 drugs in this class
argenx · 7 drugs in this class
Johnson & Johnson · 2 drugs in this class
German CLL Study Group · 2 drugs in this class
Amgen · 2 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
Brii Biosciences Limited · 2 drugs in this class
Alexion Pharmaceuticals, Inc. · 2 drugs in this class
Biotest · 2 drugs in this class
Fondazione Italiana Linfomi - ETS · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Romosozumab Prefilled Syringe — Competitive Intelligence Brief. https://druglandscape.com/ci/romosozumab-prefilled-syringe. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab